Compare NYT & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NYT | ALGN |
|---|---|---|
| Founded | 1851 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 11.9B |
| IPO Year | N/A | N/A |
| Metric | NYT | ALGN |
|---|---|---|
| Price | $69.33 | $167.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | $65.33 | ★ $187.50 |
| AVG Volume (30 Days) | ★ 1.8M | 1.1M |
| Earning Date | 02-04-2026 | 02-04-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 21.46 | N/A |
| EPS | 2.05 | ★ 5.16 |
| Revenue | $2,722,033,000.00 | ★ $3,982,622,000.00 |
| Revenue This Year | $11.06 | $2.58 |
| Revenue Next Year | $6.93 | $3.36 |
| P/E Ratio | $34.17 | ★ $31.02 |
| Revenue Growth | ★ 8.49 | 0.56 |
| 52 Week Low | $44.83 | $122.00 |
| 52 Week High | $71.23 | $237.23 |
| Indicator | NYT | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.78 | 69.76 |
| Support Level | $68.69 | $154.62 |
| Resistance Level | $70.52 | $159.16 |
| Average True Range (ATR) | 1.08 | 3.58 |
| MACD | -0.30 | -0.39 |
| Stochastic Oscillator | 60.32 | 96.16 |
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments: New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the majority source of revenue for both segments is subscription.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.